Contineum Therapeutics, Inc.

Listed Company

CTNMCIK 0001855175NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-60.00M

Total Assets

$276.64M

Equity

$260.99M

Shares Out

23.10M

Op. Cash Flow

$-55.31M

Business

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing selective small molecule therapies that modulate innate immune and inflammatory (NI&I) pathways to alter disease course. Its lead products include PIPE-791 (an LPA1 receptor antagonist), PIPE-307 (a selective M1 receptor antagonist developed with Johnson & Johnson), and CTX-343 (a peripherally-restricted LPA1 antagonist), plus discovery-stage programs such as a calpain inhibitor. Key business areas are its LPA1 franchise, the partnered PIPE-307 program with J&J, and an internal discovery pipeline. It retains worldwide rights to its LPA1 programs, leverages contract manufacturers for supply, conducts U.S. and international clinical trials, and partners for development and commercialization (J&J handles PIPE-307 commercialization while Contineum plans U.S. commercialization for PIPE-791).

Summary from filing dated 2025-03-06

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Research and development	52	38	28
General and administrative	17	12	6
Total operating expenses	68	51	34
Loss from operations	−68	−51	16
Interest income	8	9	5
Change in fair value of warrant liability	0	−106,000	5,000
Other expense, net	−165,000	−163,000	−177,000
Total other income, net	8	9	7
Net loss	−60	−42	23
Unrealized gain on marketable securities	189,000	−37,000	184,000
Comprehensive loss	−60	−42	23
Net loss per share, basic (in dollars per share)	−2.17	−2.18	1.36
Net loss per share, diluted (in dollars per share)	−2.17	−2.18	0.08
Weighted-average shares of common shares outstanding, basic (in shares)	28	19	2
Weighted-average shares of common shares outstanding, diluted (in shares)	28	19	3

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-11-30	FY 2024 2024-12-31	FY 2024 2024-09-30	FY 2023 2023-12-31
Cash and cash equivalents	76	—	22	—	16
Marketable securities	187	—	183	—	110
Prepaid expenses and other current assets	5	—	2	—	3
Total current assets	268	—	206	—	128
Property and equipment, net	830,000	—	989,000	—	678,000
Other long-term assets	256,000	—	3,000	—	1
Operating lease right-of-use assets	8	2	5	6	719,000
Total assets	277	—	213	—	130
Accounts payable	1	—	2	—	635,000
Accrued expenses	6	—	7	—	4
Current portion of operating lease liabilities	2	—	1	—	464,000
Total current liabilities	10	—	10	—	5
Operating lease liabilities, net of current portion	6	—	5	—	108,000
Total liabilities	16	—	15	—	6
Commitments and contingencies (Note 10)	—	—	—	—	—
Preferred stock, $0.001 par value; authorized shares10,000,000 at December 31, 2025 and December 31, 2024; no shares issued or outstanding at December 31, 2025 and December 31, 2024	0	—	0	—	0
Additional paid-in-capital	438	—	315	—	7
Accumulated deficit	−177	—	−117	—	−75
Accumulated other comprehensive income	260,000	—	71,000	—	108,000
Total stockholders equity	261	—	198	—	−68
Total liabilities and stockholders equity	277	—	213	—	130

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Depreciation and amortization	300,000	300,000	200,000
Non-cash operating lease expense	1	872,000	965,000
Stock-based compensation	10	7	2
Accretion of premiums/discounts on marketable securities, net	−791,000	−4	−3
Loss (gain) on sale of property and equipment	67,000	−16,000	—
Gain on marketable securities	−12,000	−5,000	19,000
Prepaid expenses and other current assets	−3	887,000	−1
Other long-term assets	3,000	937,000	7,000
Accounts payable	−869,000	1	0
Accrued expenses	−516,000	2	2
Operating lease liabilities	−1	66,000	−1
Net cash used in operating activities	−55	−33	19
Purchase of property and equipment	−231,000	−514,000	−414,000
Proceeds from sale of equipment	0	20,000	0
Purchases of marketable securities	−163	−226	−142
Sales and maturities of marketable securities	159	157	77
Net cash used in investing activities	−4	−70	−66
Payments of deferred offering costs	−256,000	0	−343,000
Proceeds from exercise of stock options	219,000	405,000	159,000
Proceeds from employee stock purchase plan	467,000	385,000	0
Net cash provided by financing activities	113	109	56
Net increase in cash and cash equivalents	54	6	10
Property and equipment purchases included in accounts payable	0	58,000	30,000
Reclassification of warrants from liability to equity	0	216,000	—
Reclassification of deferred offering costs paid in prior year to equity	0	343,000	—
Right-of-use assets obtained in exchange for lease liabilities	3	6	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro